WallStSmart

McKesson Corporation (MCK)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

McKesson Corporation generates 513% more annual revenue ($403.43B vs $65.77B). MRK leads profitability with a 13.6% profit margin vs 1.2%. MCK appears more attractively valued with a PEG of 1.49. MCK earns a higher WallStSmart Score of 55/100 (C).

MCK

Buy

55

out of 100

Grade: C

Growth: 8.0Profit: 4.5Value: 4.7Quality: 7.0
Piotroski: 5/9Altman Z: 5.40

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MCKSignificantly Overvalued (-65.1%)

Margin of Safety

-65.1%

Fair Value

$577.34

Current Price

$763.51

$186.17 premium

UndervaluedFair: $577.34Overvalued
MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$128.66

$47.70 premium

UndervaluedFair: $80.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MCK5 strengths · Avg: 9.0/10
Debt/EquityHealth
-3.9710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.4010/10

Safe zone — low bankruptcy risk

Market CapQuality
$89.39B9/10

Large-cap with strong market position

EPS GrowthGrowth
37.2%8/10

Earnings expanding 37.2% YoY

Free Cash FlowQuality
$3.31B8/10

Generating 3.3B in free cash flow

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

MCK3 concerns · Avg: 3.0/10
Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
1.2%3/10

1.2% margin — thin

Operating MarginProfitability
2.2%3/10

Operating margin of 2.2%

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MCK

The strongest argument for MCK centers on Debt/Equity, Altman Z-Score, Market Cap. PEG of 1.49 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : MCK

The primary concerns for MCK are Return on Equity, Profit Margin, Operating Margin. Thin 1.2% margins leave little buffer for downturns.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

MCK carries more volatility with a beta of 0.32 — expect wider price swings.

MCK is growing revenue faster at 6.0% — sustainability is the question.

MCK generates stronger free cash flow (3.3B), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MCK scores higher overall (55/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

McKesson Corporation

HEALTHCARE · MEDICAL DISTRIBUTION · USA

McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?